Reichle J L
Department of Radiology, Lyster US Army Hospital, Fort Rucker, Ala 36362, USA.
South Med J. 1998 Jun;91(6):510-7.
Screening mammography, particularly for women in their 40s, has become a confusing issue for many physicians. Recent scientific and political controversies regarding screening guidelines have added to this confusion.
Many randomized clinical trials have shown the benefits of mammographic screening for women over the age of 50, and recent studies show a statistically significant benefit for women in their 40s as well. Understanding the screening controversy requires an understanding of the principle of screening for disease, the epidemiology of breast cancer, and the results of the many randomized clinical trials, particularly recent data from the Swedish two-county trials. An appreciation of the improvements in mammographic quality in recent years, and in the education of the radiologists who interpret these studies, will also heighten clinical acceptance of this screening technique.
Both the American Cancer Society and American College of Radiology endorse annual mammographic screening for women over age 40, and there is compelling evidence to support these recommendations.
Radiologists, primary care providers, surgeons, and pathologists should work together to enhance the benefits of and access to screening mammography.
乳腺钼靶筛查，尤其是针对40多岁女性的筛查，已成为许多医生感到困惑的问题。近期有关筛查指南的科学和政治争议加剧了这种困惑。
许多随机临床试验表明，乳腺钼靶筛查对50岁以上女性有益，近期研究也显示对40多岁女性有统计学上的显著益处。理解筛查争议需要了解疾病筛查原则、乳腺癌流行病学以及众多随机临床试验的结果，特别是瑞典两县试验的最新数据。了解近年来乳腺钼靶质量的提高以及解读这些检查结果的放射科医生的教育情况，也将提高临床对这种筛查技术的接受度。
美国癌症协会和美国放射学会均支持对40岁以上女性进行年度乳腺钼靶筛查，且有令人信服的证据支持这些建议。
放射科医生、初级保健提供者、外科医生和病理学家应共同努力，提高乳腺钼靶筛查的益处并增加其可及性。
